Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma - Wikidata - wikimedia - TriplyDB

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

http://www.wikidata.org/entity/Q28087306

about

Radioresistance of Brain Tumors Stress Response Leading to Resistance in Glioblastoma-The Need for Innovative Radiotherapy (iRT) Concepts Development of targeted therapies in treatment of glioblastoma Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment Neuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Actionable molecular biomarkers in primary brain tumors.Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry.Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells.Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors.Associating spatial diversity features of radiologically defined tumor habitats with epidermal growth factor receptor driver status and 12-month survival in glioblastoma: methods and preliminary investigation Emerging targets for glioblastoma stem cell therapy Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner.Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.Neuro-oncology biotech industry progress report.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.The antiproliferative and apoptotic effects of apigenin on glioblastoma cells.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors.RNA processing as an alternative route to attack glioblastoma.EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment.Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.Biomarkers and therapeutic advances in glioblastoma multiforme.EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells.Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

P2860

Q26752579-90D50593-2AC2-4EC8-8C9E-40E984809FC8 Q26771706-8AE01785-F95A-48EE-AC04-9E8571F82C0A Q26778787-F4D1ED2E-F9BA-44E0-93C1-C2FF92FFDFA4 Q28078539-60B69D70-67E7-45C8-AA83-4998C94B2255 Q28078559-8F9C7E6A-4715-4145-9A22-ED87991EF32F Q30699331-134266C6-1701-480E-ABBA-10FD9C751568 Q33276007-F7B07E77-A62A-4B89-9FD8-6BD0846D10EE Q33721106-DB20B39F-8F7D-4065-ABC6-A8045DCFBD45 Q33772355-26BBDA61-2425-40AF-9234-43641E6B6C72 Q33795137-DED5A17B-7031-4899-A1DA-7590231F1BB6 Q36112877-0D7CF42D-345D-4144-A6AE-97B2C75680FF Q36179288-AC49A52F-B62A-4DE6-8096-5D36015145D9 Q36247876-7A8585EC-F6D9-4BD0-8C1D-B7BA2DCAED27 Q36270828-586AC399-48E5-417D-AAD8-C64BC611D67F Q36478699-9614A83C-F7E5-4E4E-8726-F483B2D7DFEB Q36502009-5AA646E9-3B70-4DFB-A0C7-6581062F9B9F Q36665167-3499ED89-E0D9-45B2-8089-71A3044E581C Q37362563-1B493A74-B352-4926-8EBB-43ACEAB587D3 Q37690917-CB9A45AC-60AF-46AD-8786-2A1E54F8A66D Q38697698-57BF52A5-34AF-4350-B9CE-5BA214C0F384 Q38733038-0D0C5AC9-BBBA-4753-85C6-0C5D6E75B29F Q38741932-0EE485E5-3F13-4341-A4F1-9B33CE4DBE96 Q38743138-2D17A489-81F4-48EF-99E3-4DE73EA88AFD Q38759795-8F2E66A3-9B05-487D-AAD4-451DFA1EFFA9 Q38832105-DD8CA082-B684-4A29-9B37-8A8954332A33 Q38871823-5750C595-0E4D-48A4-BDD8-1400FDB8E72B Q38987239-BE0CCF80-600E-4539-865B-F9174A65595C Q38998571-124C5DEA-97E2-46C2-A69C-B663247234E7 Q39139224-91CF41BC-126A-4CA5-B9EE-F4B2A2A1C8FC Q39368650-FAA2DB44-ADC7-4279-B57B-840D8670AEB7 Q39383476-2D5A135E-AAA9-4D0D-BEB6-2B6E5DD52590 Q39428273-BF65F33F-B804-4950-9E47-F88D6CBAE5DF Q40070524-BE386583-BE8B-493B-B275-EF69CA62BCC6 Q40089704-D8C41D91-51B7-44DC-832E-2FF41BB507F6 Q40190070-8FC33835-5A44-4ADA-A0C3-00BD9B34CBC7 Q41192103-4F4BB2A3-5824-4234-9776-9339383E905F Q42365122-1AF7AE58-3B60-476F-B8F2-784F9126560B Q42775850-DA5AAF8E-B38A-4C67-A030-A2A70A657B2B Q45946525-4A49C689-A629-458C-BD82-5706B5F50E70 Q45997277-D8DA1D87-C5C7-4587-A845-18A0D74EEDB5

P2860

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

http://www.wikidata.org/entity/Q28087306

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@ast

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@en

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@nl

type

label

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@ast

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@en

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@nl

prefLabel

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@ast

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@en

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@nl

P1433

Q28087306-809D1ED8-7232-42E8-A06B-54FB6D759001

P1476

Q28087306-B3FA40B3-D7F6-4FD2-9852-5C8BD87E2BD2

P2093

Q28087306-65657B94-07C4-4260-B50F-073060A81D65

Q28087306-C260D750-47D9-41A5-AF0F-E48DC69C656F

Q28087306-E57F181F-9245-4375-9B10-C4230CA51C41

P2860

Q28087306-0141340A-4C01-4672-8F44-D69B5DD95533

Q28087306-019CEA82-2A81-4427-88A9-78C402E96BDE

Q28087306-0499C161-2471-4DD9-AF14-DFA78110E061

Q28087306-068D90CA-7A8D-4827-8318-AF89827943D9

Q28087306-0A7A38B2-15A2-4DC0-B25F-11D29CEC8302

Q28087306-0AAC9C56-6BAE-40A8-AB80-E1AF4451F070

Q28087306-0D7EABFF-71AA-4D59-9655-F7840F01F057

Q28087306-0E9AB124-913B-44CF-88A1-AFBB2B3C6A6A

Q28087306-12164D49-C726-421F-97E0-B0286E394695

Q28087306-18ADABBC-D575-4652-BB70-D820D44A1DA5

P304

Q28087306-A19BAA68-79F2-412D-9E5E-7C2BFA7FF6D4

P31

Q28087306-CF331445-D721-4847-A591-AE2AE0D6517A

P3181

Q28087306-22215E8F-9EFC-4DAD-BDAE-1A1E9AED1F39

P356

Q28087306-AE290A15-EB8A-44C9-AAEC-999E9C259BF2

P407

Q28087306-EEB564EE-E6FB-4924-82D6-C62A171049D6

P478

Q28087306-DEEAA66D-4817-4468-A6FB-BFBD98D0B1F9

P577

Q28087306-E0DA7CFF-D05C-48A1-BA64-E817CA3A9650

P5875

Q28087306-FE1F4AF8-0DCD-40AD-92D1-E7C26A304007

P698

Q28087306-F771CAA5-F11F-4125-9571-99C80D1E770A

P932

Q28087306-E00CDFDB-2CC1-4CC3-BFA6-805100F20CD3

P3181

P356

FONC.2015.00005

P1433

Frontiers in Oncology

P1476

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

@en

P2093

Emily Padfield

http://www.w3.org/2001/XMLSchema#string

Hayley P. Ellis

http://www.w3.org/2001/XMLSchema#string

Kathreena M. Kurian

http://www.w3.org/2001/XMLSchema#string

P2860

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma

An integrated genomic analysis of human glioblastoma multiforme

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The promises and pitfalls of RNA-interference-based therapeutics

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours

The natural history of EGFR and EGFRvIII in glioblastoma patients

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

P304

5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2150219

http://www.w3.org/2001/XMLSchema#string

P356

10.3389/FONC.2015.00005

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272512073

http://www.w3.org/2001/XMLSchema#string

P698

25688333

http://www.w3.org/2001/XMLSchema#string

P932

4310282

http://www.w3.org/2001/XMLSchema#string